Skip to content

Comparing Surgical Management Methods of Atrial Fibrillation

Prospective, Randomized Trial Comparing Left Atrial Cox-Maze IV, Tampa 2 or Encompass Alone, Ablation in the Surgical Management of Atrial Fibrillation

Status
Enrolling by invitation
Phases
Unknown
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT07100483
Enrollment
220
Registered
2025-08-03
Start date
2025-09-15
Completion date
2032-09-15
Last updated
2026-07-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Atrial Fibrillation

Keywords

AFib, Ablation, Cox IV, Tampa 2, Encompass, Box Lesion

Brief summary

Compare the efficacy of the left atrial Cox-Maze IV lesion set versus the Tampa 2 lesion set versus the EnCompass ablation alone, in the surgical treatment of atrial fibrillation at one year post-operatively.

Detailed description

This is a single center prospective, randomized trial to compare the outcomes, specifically the freedom from atrial fibrillation at one year, and possibly up to five years, of three different approaches to the cardiac surgical management of atrial fibrillation. Several strategies to accomplish surgical ablation are acceptable and have been shown retrospectively to be successful. The Cox-Maze bi-atrial, left and right atrial lesions, ablation (whether III or IV) remains the gold standard by which all surgical ablations are compared. Further refinement in ablation technology and research has further suggested there is no difference between a left atrial ablation alone or bi-atrial ablation lesion set. For left atrial ablation alone, existent therapeutic options, which all meet equivalent standard of care, include a left atrial Cox-Maze IV , a Tampa 2 lesion set or utilizing a "box lesion" alone. Currently, there are no randomized, clinical trials demonstrating better efficacy (freedom from atrial fibrillation post-operatively) of one ablation strategy over another in patients undergoing cardiac surgery. The rationale for the study is to demonstrate whether one ablation technique is more efficacious in the surgical treatment of AF. Should one technique prove superior it may clarify the question of which ablation strategy to utilize and encourage surgeons to implement a consistent approach to surgical ablation. To our knowledge this study would be the first prospective, randomized trial in the United States comparing surgical lesion sets in the concomitant management of atrial fibrillation.

Interventions

PROCEDUREAtrial Fibrillation Ablation

Ablation of the heart to reduce Afib Occurrence

Sponsors

Corewell Health West
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Intervention model description

This is a single enter prospective, randomized trial to compare the outcomes, specifically the freedom from atrial fibrillation at one year, and possibly up to five years, of three different approaches (Cox-Maze IV, Tampa 2, Encompass) to the cardiac surgical management of atrial fibrillation. All patients undergoing an elective, cardiac surgical procedure with documented preoperative AF, either paroxysmal or persistent, with a planned surgical ablation are potential candidates.

Eligibility

Sex/Gender
ALL
Age
18 Years to 85 Years
Healthy volunteers
No

Inclusion criteria

* Adult patients with a history of preoperative atrial fibrillation, either paroxysmal or persistent, requiring concomitant surgical ablation who are scheduled to undergo cardiac surgical procedure(s) to be performed on cardiopulmonary bypass * Utilizing sternotomy approach requiring cardiopulmonary bypass * Male or Female subjects between age 18 to 85 years of age

Exclusion criteria

* LVEF \< 25% * LAVI \> 59ml/m② * Presence of Pacemaker/AICD * History of VT/VF, WPW * Re-operative cardiac surgery

Design outcomes

Primary

MeasureTime frameDescription
Freedom from Atrial Fibrillation30 days and 1 yearFreedom from atrial fibrillation at 30 days and one year

Secondary

MeasureTime frameDescription
Prescribed Antiarrhythmic and anticoagulant drugs7 days and 1 yearAntiarrhythmic and anticoagulant drugs at 7days and one year post surgery

Countries

United States

Contacts

PRINCIPAL_INVESTIGATORCharles Willekes, MD

Corewell Health

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Jul 17, 2026